Hui Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hui Chen has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Geyang Xu
Department of Physiology, School of Medicine, Jinan University, Guangzhou, China
6 shared publications Jinghui Guo
School of Medicine, The Chinese University of Hong Kong, Shenzhen, China
6 shared publicationsTian Tao
Department of Physiology School of Medicine Jinan University Guangzhou China
6 shared publicationsJie Yang
Department of Pathology, School of Basic Medicine, Guangzhou Medical University
5 shared publicationsJingya Lyu
Department of Physiology, School of Medicine, Jinan University
5 shared publicationsQimeng Wang
Biotherapy Center The Third Affiliated Hospital Sun Yat‐Sen University Guangzhou Guangdong China
5 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 7774
Publisher Correction: CFTR mediates Cl- transport in osteocytes to sustain cell viability and skeletal homeostasis
- 4 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 7774
Open AccessPublisher Correction: CFTR mediates Cl- transport in osteocytes to sustain cell viability and skeletal homeostasis
- Open Access
- 28 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
CFTR mediates Cl- transport in osteocytes to sustain cell viability and skeletal homeostasis
Osteocytes are long-lived with underlying mechanisms largely unknown. Here, we report that osteocyte-specific knockout of cystic fibrosis transmembrane conductance regulator (CFTR) results in excessive osteocyte death, proinflammatory cytokine surge, osteoclast overactivation and bone formation impairment leading to bone loss in adult mice. Consistently in MLO‑Y4 osteocyte‑line, CFTR-knockout causes progressive cell death, which is reversed by CFTR overexpression or medium replenishment. A massive proinflammatory osteocyte secretome is evoked by CFTR-knockout, which deteriorates wild-type osteocytes, inhibits osteogenic differentiation, while robustly stimulates osteoclastogenic differentiation in vitro. Patch-clamp/Cl--imaging verifies CFTR to mediate Cl- transport in osteocytes, while Cl--deprivation mimics CFTR-knockout to trigger transcriptomic/proteomic changes, cell stress and death. Additionally, osteocyte CFTR is downregulated in aged human bones; local delivery of CFTR via adenovirus or a CFTR modulator increases viable osteocytes and bone mass in aged mice. Together, the present study reveals a direct role of CFTR-mediated Cl- transport in sustaining osteocyte viability and skeletal homeostasis.
- 28 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessCFTR mediates Cl- transport in osteocytes to sustain cell viability and skeletal homeostasis
Osteocytes are long-lived with underlying mechanisms largely unknown. Here, we report that osteocyte-specific knockout of cystic fibrosis transmembrane conductance regulator (CFTR) results in excessive osteocyte death, proinflammatory cytokine surge, osteoclast overactivation and bone formation impairment leading to bone loss in adult mice. Consistently in MLO‑Y4 osteocyte‑line, CFTR-knockout causes progressive cell death, which is reversed by CFTR overexpression or medium replenishment. A massive proinflammatory osteocyte secretome is evoked by CFTR-knockout, which deteriorates wild-type osteocytes, inhibits osteogenic differentiation, while robustly stimulates osteoclastogenic differentiation in vitro. Patch-clamp/Cl--imaging verifies CFTR to mediate Cl- transport in osteocytes, while Cl--deprivation mimics CFTR-knockout to trigger transcriptomic/proteomic changes, cell stress and death. Additionally, osteocyte CFTR is downregulated in aged human bones; local delivery of CFTR via adenovirus or a CFTR modulator increases viable osteocytes and bone mass in aged mice. Together, the present study reveals a direct role of CFTR-mediated Cl- transport in sustaining osteocyte viability and skeletal homeostasis.
- Open Access
- 3 April 2026
- Published by Wiley in Advanced Science
- Vol. 13 (34) , e15847
Hepatocyte PIEZO1 Negatively Regulates Lipogenesis and Ameliorates MASLD by Sensing Membrane Tension and Activating AMPK
Liver is a central organ for lipid metabolism. Disruption of lipid homeostasis leads to lipid accumulation in hepatocytes, which is a feature of metabolic dysfunction‐associated steatotic liver disease (MASLD). Mechanical force and mechanosensitive proteins have been found to play a crucial role in energy metabolism. However, their role in hepatic lipid metabolism remains unclear. In this study, mechanosensitive ion channel PIEZO1 is detected in hepatocytes, and downregulated in the liver of MASLD patients and high‐fat diet (HFD)‐induced MASLD mouse model. Under HFD feeding, mice with hepatocyte‐specific Piezo1 deletion exhibit severer triglyceride accumulation, upregulation of de novo lipogenesis genes, and decreased phosphorylation of AMPK and RAPTOR in the liver. In contrast, injection of PIEZO1 activator Yoda1 alleviates triglyceride accumulation, downregulates lipogenesis genes and enhances phosphorylation of AMPK and RAPTOR in HFD‐fed C57BL/6 mice. Knockdown of PIEZO1 in HepG2 leads to upregulation of lipogenesis genes and impairs AMPK‐RAPTOR pathway, while Yoda1 or hypotonic treatment do the reverse. The effects of PIEZO1 knockdown and Yoda1 treatment can be abolished by AMPK activator and CaMKK2/AMPK inhibitors, respectively. These findings suggest that PIEZO1 can respond to changes in membrane tension and activate AMPK, thereby inhibiting lipogenesis and maintaining lipid homeostasis.
- 3 April 2026
- Published by Wiley in Advanced Science
- Vol. 13 (34) , e15847
Open AccessHepatocyte PIEZO1 Negatively Regulates Lipogenesis and Ameliorates MASLD by Sensing Membrane Tension and Activating AMPK
Liver is a central organ for lipid metabolism. Disruption of lipid homeostasis leads to lipid accumulation in hepatocytes, which is a feature of metabolic dysfunction‐associated steatotic liver disease (MASLD). Mechanical force and mechanosensitive proteins have been found to play a crucial role in energy metabolism. However, their role in hepatic lipid metabolism remains unclear. In this study, mechanosensitive ion channel PIEZO1 is detected in hepatocytes, and downregulated in the liver of MASLD patients and high‐fat diet (HFD)‐induced MASLD mouse model. Under HFD feeding, mice with hepatocyte‐specific Piezo1 deletion exhibit severer triglyceride accumulation, upregulation of de novo lipogenesis genes, and decreased phosphorylation of AMPK and RAPTOR in the liver. In contrast, injection of PIEZO1 activator Yoda1 alleviates triglyceride accumulation, downregulates lipogenesis genes and enhances phosphorylation of AMPK and RAPTOR in HFD‐fed C57BL/6 mice. Knockdown of PIEZO1 in HepG2 leads to upregulation of lipogenesis genes and impairs AMPK‐RAPTOR pathway, while Yoda1 or hypotonic treatment do the reverse. The effects of PIEZO1 knockdown and Yoda1 treatment can be abolished by AMPK activator and CaMKK2/AMPK inhibitors, respectively. These findings suggest that PIEZO1 can respond to changes in membrane tension and activate AMPK, thereby inhibiting lipogenesis and maintaining lipid homeostasis.
- Open Access
- 13 November 2025
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 82 (1) , 1-14
Hepatocyte Piezo1 regulates glycogen metabolism via the FGF21-STAT3 pathway
The metabolism of glycogen in the liver plays a crucial role in regulating blood glucose levels. Previous studies have underscored the critical involvement of Piezo1 in glucose metabolism. However, the role of Piezo1 in hepatic glycogen metabolism remain unexplored. We induced liver-specific deletion of Piezo1 in Piezo1fl/fl mice using Cre adenovirus via tail vein injection. Compared to Piezo1fl/fl treated with GFP adenovirus, those treated with AAV-Cre exhibited impaired glucose tolerance, elevated GYS2 and PYGL levels, and decreased FGF21 levels, implicating inhibition of the STAT3 signaling pathway. Furthermore, mice with hepatocyte-specific Piezo1 deletion (Alb-Piezo1−/−) on a high-fat diet experienced exacerbated blood glucose levels, decreased hepatic FGF21 production, and enhanced PYGL expression and activity. These effects were alleviated by PF-05231023, an FGF21 analog. Additionally, intraperitoneal injection of Yoda1, a Piezo1 agonist, raised FGF21 levels, activating the STAT3 pathway and suppressing PYGL activity, thereby improving glucose tolerance. In vitro studies showed that knockdown of Piezo1 or Stat3 increased PYGL expression. Conversely, activation of Piezo1 led to decreased PYGL expression. Our study reveals a previously unexplored regulatory mechanism of glycogen metabolism by Piezo1 in liver cells, offering new insights into diabetes treatment. Graphical abstract
- 13 November 2025
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 82 (1) , 1-14
Open AccessHepatocyte Piezo1 regulates glycogen metabolism via the FGF21-STAT3 pathway
The metabolism of glycogen in the liver plays a crucial role in regulating blood glucose levels. Previous studies have underscored the critical involvement of Piezo1 in glucose metabolism. However, the role of Piezo1 in hepatic glycogen metabolism remain unexplored. We induced liver-specific deletion of Piezo1 in Piezo1fl/fl mice using Cre adenovirus via tail vein injection. Compared to Piezo1fl/fl treated with GFP adenovirus, those treated with AAV-Cre exhibited impaired glucose tolerance, elevated GYS2 and PYGL levels, and decreased FGF21 levels, implicating inhibition of the STAT3 signaling pathway. Furthermore, mice with hepatocyte-specific Piezo1 deletion (Alb-Piezo1−/−) on a high-fat diet experienced exacerbated blood glucose levels, decreased hepatic FGF21 production, and enhanced PYGL expression and activity. These effects were alleviated by PF-05231023, an FGF21 analog. Additionally, intraperitoneal injection of Yoda1, a Piezo1 agonist, raised FGF21 levels, activating the STAT3 pathway and suppressing PYGL activity, thereby improving glucose tolerance. In vitro studies showed that knockdown of Piezo1 or Stat3 increased PYGL expression. Conversely, activation of Piezo1 led to decreased PYGL expression. Our study reveals a previously unexplored regulatory mechanism of glycogen metabolism by Piezo1 in liver cells, offering new insights into diabetes treatment. Graphical abstract
- Open Access
- 1 March 2025
- Published by KEAI Publishing in Liver Research
- Vol. 9 (1) , 36-48
Mechanosensitive ion channel-related genes in hepatocellular carcinoma: Unraveling prognostic genes and their roles in drug resistance and immune modulation
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, and its etiology involves a complex interplay of genetic and environmental factors. Despite advancements in our understanding of HCC biology and the development of novel therapeutic strategies, the molecular mechanisms underlying its onset, progression, and resistance to therapy remain largely vague. This study aimed to investigate the role of mechanosensitive ion channel-related genes (MICRGs) in HCC, focusing on their potential as prognostic biomarkers and their involvement in immune modulation and drug resistance. A comprehensive analysis was conducted using The Cancer Genome Atlas database to identify MICRGs that are upregulated in HCC. Gene expression profiling, bioinformatics tools, and functional experiments were employed to elucidate the role of these channels. In addition, protein–protein interaction (PPI) network analyses and enrichment analyses were performed to explore the biological significance of these genes. An immune cell infiltration analysis was also conducted to understand MICRG-related immune landscape. Single-cell RNA sequencing (scRNA-seq) data were utilized to identify MICRGs in different cell types within the HCC tissue. Deep-learning neural network analysis across patient cohorts was conducted to identify genes associated with sorafenib resistance. Knockdown experiments, cell viability assays, and apoptosis assays on HCC cell lines were performed to examine the role of Piezo-type mechanosensitive ion channel component 1 (PIEZO1) in sorafenib resistance. The analysis identified a subset of MICRGs, including PIEZO1, that were significantly upregulated in HCC and associated with poor prognosis. The PPI network analysis revealed complex interactions among these genes. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses proposed the involvement of these genes in calcium signaling pathways. Immune cell infiltration analysis demonstrated distinct associations between MICRGs and various immune subpopulations, highlighting their potential roles in immune modulation. scRNA-seq data indicated the upregulation of MICRGs in various cell types in HCC tissues, particularly in endothelial cells and tumor-associated macrophages. Deep-learning neural network analysis across different patient cohorts identified PIEZO1 as a crucial regulator of sorafenib resistance in HCC, which was further validated by functional assays on HCC cell lines. This study provides evidence that MICRGs, particularly PIEZO1, take on crucial roles in HCC progression and drug resistance. The upregulation of PIEZO1 in HCC cells is associated with poor prognosis and resistance to sorafenib. These findings indicate that PIEZO1 could serve as a potential therapeutic target for overcoming drug resistance and a prognostic biomarker in HCC. Future studies should focus on validating these findings in larger patient cohorts and exploring the functional implications of targeting PIEZO1 in preclinical models.
- 1 March 2025
- Published by KEAI Publishing in Liver Research
- Vol. 9 (1) , 36-48
Open AccessMechanosensitive ion channel-related genes in hepatocellular carcinoma: Unraveling prognostic genes and their roles in drug resistance and immune modulation
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, and its etiology involves a complex interplay of genetic and environmental factors. Despite advancements in our understanding of HCC biology and the development of novel therapeutic strategies, the molecular mechanisms underlying its onset, progression, and resistance to therapy remain largely vague. This study aimed to investigate the role of mechanosensitive ion channel-related genes (MICRGs) in HCC, focusing on their potential as prognostic biomarkers and their involvement in immune modulation and drug resistance. A comprehensive analysis was conducted using The Cancer Genome Atlas database to identify MICRGs that are upregulated in HCC. Gene expression profiling, bioinformatics tools, and functional experiments were employed to elucidate the role of these channels. In addition, protein–protein interaction (PPI) network analyses and enrichment analyses were performed to explore the biological significance of these genes. An immune cell infiltration analysis was also conducted to understand MICRG-related immune landscape. Single-cell RNA sequencing (scRNA-seq) data were utilized to identify MICRGs in different cell types within the HCC tissue. Deep-learning neural network analysis across patient cohorts was conducted to identify genes associated with sorafenib resistance. Knockdown experiments, cell viability assays, and apoptosis assays on HCC cell lines were performed to examine the role of Piezo-type mechanosensitive ion channel component 1 (PIEZO1) in sorafenib resistance. The analysis identified a subset of MICRGs, including PIEZO1, that were significantly upregulated in HCC and associated with poor prognosis. The PPI network analysis revealed complex interactions among these genes. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses proposed the involvement of these genes in calcium signaling pathways. Immune cell infiltration analysis demonstrated distinct associations between MICRGs and various immune subpopulations, highlighting their potential roles in immune modulation. scRNA-seq data indicated the upregulation of MICRGs in various cell types in HCC tissues, particularly in endothelial cells and tumor-associated macrophages. Deep-learning neural network analysis across different patient cohorts identified PIEZO1 as a crucial regulator of sorafenib resistance in HCC, which was further validated by functional assays on HCC cell lines. This study provides evidence that MICRGs, particularly PIEZO1, take on crucial roles in HCC progression and drug resistance. The upregulation of PIEZO1 in HCC cells is associated with poor prognosis and resistance to sorafenib. These findings indicate that PIEZO1 could serve as a potential therapeutic target for overcoming drug resistance and a prognostic biomarker in HCC. Future studies should focus on validating these findings in larger patient cohorts and exploring the functional implications of targeting PIEZO1 in preclinical models.
- Open Access
- 7 November 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Mechano-regulation of GLP-1 production by Piezo1 in intestinal L cells
Glucagon-like peptide 1 (GLP-1) is a gut-derived hormone secreted by intestinal L cells and vital for postprandial glycemic control. As open-type enteroendocrine cells, whether L cells can sense mechanical stimuli caused by chyme and thus regulate GLP-1 synthesis and secretion is unexplored. Molecular biology techniques revealed the expression of Piezo1 in intestinal L cells. Its level varied in different energy status and correlates with blood glucose and GLP-1 levels. Mice with L cell-specific loss of Piezo1 ( Piezo1 IntL-CKO) exhibited impaired glucose tolerance, increased body weight, reduced GLP-1 production and decreased CaMKKβ/CaMKIV-mTORC1 signaling pathway under normal chow diet or high-fat diet. Activation of the intestinal Piezo1 by its agonist Yoda1 or intestinal bead implantation increased the synthesis and secretion of GLP-1, thus alleviated glucose intolerance in diet-induced-diabetic mice. Overexpression of Piezo1, Yoda1 treatment or stretching stimulated GLP-1 production and CaMKKβ/CaMKIV-mTORC1 signaling pathway, which could be abolished by knockdown or blockage of Piezo1 in primary cultured mouse L cells and STC-1 cells. These experimental results suggest a previously unknown regulatory mechanism for GLP-1 production in L cells, which could offer new insights into diabetes treatments.
- 7 November 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Open AccessMechano-regulation of GLP-1 production by Piezo1 in intestinal L cells
Glucagon-like peptide 1 (GLP-1) is a gut-derived hormone secreted by intestinal L cells and vital for postprandial glycemic control. As open-type enteroendocrine cells, whether L cells can sense mechanical stimuli caused by chyme and thus regulate GLP-1 synthesis and secretion is unexplored. Molecular biology techniques revealed the expression of Piezo1 in intestinal L cells. Its level varied in different energy status and correlates with blood glucose and GLP-1 levels. Mice with L cell-specific loss of Piezo1 ( Piezo1 IntL-CKO) exhibited impaired glucose tolerance, increased body weight, reduced GLP-1 production and decreased CaMKKβ/CaMKIV-mTORC1 signaling pathway under normal chow diet or high-fat diet. Activation of the intestinal Piezo1 by its agonist Yoda1 or intestinal bead implantation increased the synthesis and secretion of GLP-1, thus alleviated glucose intolerance in diet-induced-diabetic mice. Overexpression of Piezo1, Yoda1 treatment or stretching stimulated GLP-1 production and CaMKKβ/CaMKIV-mTORC1 signaling pathway, which could be abolished by knockdown or blockage of Piezo1 in primary cultured mouse L cells and STC-1 cells. These experimental results suggest a previously unknown regulatory mechanism for GLP-1 production in L cells, which could offer new insights into diabetes treatments.
- Open Access
- 14 October 2024
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 13
Mechano-regulation of GLP-1 production by Piezo1 in intestinal L cells
Glucagon-like peptide 1 (GLP-1) is a gut-derived hormone secreted by intestinal L cells and vital for postprandial glycemic control. As open-type enteroendocrine cells, whether L cells can sense mechanical stimuli caused by chyme and thus regulate GLP-1 synthesis and secretion is unexplored. Our study showed expression of Piezo1 in intestinal L cells. Its level varied in different energy status and correlates with blood glucose and GLP-1 levels. Mice with L cell-specific loss of Piezo1 (IntL-Piezo1-/-) exhibited impaired glucose tolerance, increased body weight, reduced GLP-1 production and decreased CaMKKβ/CaMKIV-mTORC1 signaling pathway under normal chow diet or high fed diet. Activation of the intestinal Piezo1 by its agonist Yoda1 or intestinal bead implantation increased the synthesis and secretion of GLP-1, thus alleviated glucose intolerance in diet-induced-diabetic mice. Overexpression of Piezo1, Yoda1 treatment or stretching stimulated GLP-1 production and CaMKKβ/CaMKIV-mTORC1 signaling pathway, which could be abolished by knockdown or blockage of Piezo1 in primary cultured mouse L cells and STC-1 cells. These findings suggest a previously undiscovered mechano-regulation of GLP-1 production in L cells, which may shed new light on the treatments of diabetes.
- 14 October 2024
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 13
Open AccessMechano-regulation of GLP-1 production by Piezo1 in intestinal L cells
Glucagon-like peptide 1 (GLP-1) is a gut-derived hormone secreted by intestinal L cells and vital for postprandial glycemic control. As open-type enteroendocrine cells, whether L cells can sense mechanical stimuli caused by chyme and thus regulate GLP-1 synthesis and secretion is unexplored. Our study showed expression of Piezo1 in intestinal L cells. Its level varied in different energy status and correlates with blood glucose and GLP-1 levels. Mice with L cell-specific loss of Piezo1 (IntL-Piezo1-/-) exhibited impaired glucose tolerance, increased body weight, reduced GLP-1 production and decreased CaMKKβ/CaMKIV-mTORC1 signaling pathway under normal chow diet or high fed diet. Activation of the intestinal Piezo1 by its agonist Yoda1 or intestinal bead implantation increased the synthesis and secretion of GLP-1, thus alleviated glucose intolerance in diet-induced-diabetic mice. Overexpression of Piezo1, Yoda1 treatment or stretching stimulated GLP-1 production and CaMKKβ/CaMKIV-mTORC1 signaling pathway, which could be abolished by knockdown or blockage of Piezo1 in primary cultured mouse L cells and STC-1 cells. These findings suggest a previously undiscovered mechano-regulation of GLP-1 production in L cells, which may shed new light on the treatments of diabetes.
- 24 May 2024
- Published by Springer Nature in Endocrine
- Vol. 86 (2) , 860-861
Correction to: Androgen-induced upregulation of CFTR in pancreatic β-cell contributes to hyperinsulinemia in PCOS model
- 24 May 2024
- Published by Springer Nature in Endocrine
- Vol. 86 (2) , 860-861
Correction to: Androgen-induced upregulation of CFTR in pancreatic β-cell contributes to hyperinsulinemia in PCOS model
- Open Access
Mechano-regulation of GLP-1 production by Piezo1 in intestinal L cells
Glucagon-like peptide 1 (GLP-1) is a gut-derived hormone secreted by intestinal L cells and vital for postprandial glycemic control. As open-type enteroendocrine cells, whether L cells can sense mechanical stimuli caused by chyme and thus regulate GLP-1 synthesis and secretion is unexplored. Our study showed expression of Piezo1 in intestinal L cells. Its level varied in different energy status and correlates with blood glucose and GLP-1 levels. Mice with L cell-specific loss of Piezo1 ( IntL-Piezo1 -/- ) exhibited impaired glucose tolerance, increased body weight, reduced GLP-1 production and decreased CaMKKβ/CaMKIV-mTORC1 signaling pathway under normal chow diet or high fed diet. Activation of the intestinal Piezo1 by its agonist Yoda1 or intestinal bead implantation increased the synthesis and secretion of GLP-1, thus alleviated glucose intolerance in diet-induced-diabetic mice. Overexpression of Piezo1, Yoda1 treatment or stretching stimulated GLP-1 production and CaMKKβ/CaMKIV-mTORC1 signaling pathway, which could be abolished by knockdown or blockage of Piezo1 in primary cultured mouse L cells and STC-1 cells. These findings suggest a previously undiscovered mechano-regulation of GLP-1 production in L cells, which may shed new light on the treatments of diabetes.
Open AccessMechano-regulation of GLP-1 production by Piezo1 in intestinal L cells
Glucagon-like peptide 1 (GLP-1) is a gut-derived hormone secreted by intestinal L cells and vital for postprandial glycemic control. As open-type enteroendocrine cells, whether L cells can sense mechanical stimuli caused by chyme and thus regulate GLP-1 synthesis and secretion is unexplored. Our study showed expression of Piezo1 in intestinal L cells. Its level varied in different energy status and correlates with blood glucose and GLP-1 levels. Mice with L cell-specific loss of Piezo1 ( IntL-Piezo1 -/- ) exhibited impaired glucose tolerance, increased body weight, reduced GLP-1 production and decreased CaMKKβ/CaMKIV-mTORC1 signaling pathway under normal chow diet or high fed diet. Activation of the intestinal Piezo1 by its agonist Yoda1 or intestinal bead implantation increased the synthesis and secretion of GLP-1, thus alleviated glucose intolerance in diet-induced-diabetic mice. Overexpression of Piezo1, Yoda1 treatment or stretching stimulated GLP-1 production and CaMKKβ/CaMKIV-mTORC1 signaling pathway, which could be abolished by knockdown or blockage of Piezo1 in primary cultured mouse L cells and STC-1 cells. These findings suggest a previously undiscovered mechano-regulation of GLP-1 production in L cells, which may shed new light on the treatments of diabetes.
- 11 March 2024
- Published by Springer Nature in Nature Metabolism
- Vol. 6 (3) , 458-472
Gastric mechanosensitive channel Piezo1 regulates ghrelin production and food intake
Ghrelin, produced mainly by gastric X/A-like cells, triggers a hunger signal to the central nervous system to stimulate appetite. It remains unclear whether X/A-like cells sense gastric distention and thus regulate ghrelin production. Here we show that PIEZO1 expression in X/A-like cells decreases in patients with obesity when compared to controls, whereas it increases after sleeve gastrectomy. Male and female mice with specific loss of Piezo1 in X/A-like cells exhibit hyperghrelinaemia and hyperphagia and are more susceptible to overweight. These phenotypes are associated with impairment of the gastric CaMKKII/CaMKIV–mTOR signalling pathway. Activation of PIEZO1 by Yoda1 or gastric bead implantation inhibits ghrelin production, decreases energy intake and induces weight loss in mice. Inhibition of ghrelin production by Piezo1 through the CaMKKII/CaMKIV–mTOR pathway can be recapitulated in a ghrelin-producing cell line mHypoE-42. Our study reveals a mechanical regulation of ghrelin production and appetite by PIEZO1 of X/A-like cells, which suggests a promising target for anti-obesity therapy.
- 11 March 2024
- Published by Springer Nature in Nature Metabolism
- Vol. 6 (3) , 458-472
Gastric mechanosensitive channel Piezo1 regulates ghrelin production and food intake
Ghrelin, produced mainly by gastric X/A-like cells, triggers a hunger signal to the central nervous system to stimulate appetite. It remains unclear whether X/A-like cells sense gastric distention and thus regulate ghrelin production. Here we show that PIEZO1 expression in X/A-like cells decreases in patients with obesity when compared to controls, whereas it increases after sleeve gastrectomy. Male and female mice with specific loss of Piezo1 in X/A-like cells exhibit hyperghrelinaemia and hyperphagia and are more susceptible to overweight. These phenotypes are associated with impairment of the gastric CaMKKII/CaMKIV–mTOR signalling pathway. Activation of PIEZO1 by Yoda1 or gastric bead implantation inhibits ghrelin production, decreases energy intake and induces weight loss in mice. Inhibition of ghrelin production by Piezo1 through the CaMKKII/CaMKIV–mTOR pathway can be recapitulated in a ghrelin-producing cell line mHypoE-42. Our study reveals a mechanical regulation of ghrelin production and appetite by PIEZO1 of X/A-like cells, which suggests a promising target for anti-obesity therapy.